Related Experiment Video
Updated: Sep 30, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Circulating FAM19A5 level is associated with the presence and severity of coronary artery disease
Insights
Lower serum levels of Family with sequence similarity 19 member A5 (FAM19A5) are linked to coronary artery disease (CAD). FAM19A5 may serve as a novel biomarker for diagnosing CAD and indicating its severity.
Area of Science:
- Cardiovascular Research
- Biomarker Discovery
- Adipokine Function
Background:
- Family with sequence similarity 19 member A5 (FAM19A5) is a novel adipokine with anti-inflammatory properties.
- Its role in cardiovascular disease, specifically coronary artery disease (CAD), is not well understood.
Purpose of the Study:
- To investigate the association between serum FAM19A5 levels and the presence and severity of CAD.
- To evaluate FAM19A5 as a potential biomarker for CAD diagnosis and severity assessment.
Main Methods:
- Serum FAM19A5 levels were measured in 186 CAD patients and 58 non-CAD controls.
- Coronary artery stenosis severity was quantified using the Gensini score.
- Logistic and linear regression analyses were employed to assess relationships.
Main Results:
- CAD patients exhibited significantly lower serum FAM19A5 levels compared to non-CAD controls.
- Decreased FAM19A5 was identified as a risk factor for CAD (OR: 0.563, P < 0.001).
- Serum FAM19A5 levels showed a negative correlation with the Gensini score, indicating severity.
Conclusions:
- Serum FAM19A5 levels are negatively associated with both the presence and severity of CAD.
- FAM19A5 shows promise as a novel biomarker for diagnosing CAD and indicating its severity.
Background:
Family with sequence similarity 19 member A5 (FAM19A5) has been identified as a novel adipokine that plays an important role in inhibiting inflammation and vascular smooth muscle cell proliferation. However, the clinical associations between FAM19A5 levels and the presence and severity of coronary artery disease (CAD) remains uncertain.
Methods:
We measured serum FAM19A5 levels in 186 CAD patients and 58 non-CAD patients who underwent coronary arteriography (CAG) recruited in Shanxi Medical University Affiliated Second Hospital. The severity of coronary artery stenosis was represented in the Gensini score. Logistic and linear regression analyses were used to analyze the relationship between serum FAM19A5 and CAD.
Results:
Serum FAM19A5 levels in CAD group were significantly lower than those in the non-CAD group [1.53 (1.13-2.27) ng/mL vs 2.33 (1.69-3.51) ng/mL; P = 0.013]. Logistic regression analysis showed that decreased serum FAM19A5 level was a risk factor for CAD (OR: 0.563, 95% CI: 0.409-0.776, P < 0.001). Circulating FAM19A5 levels were negatively associated with the Gensini score. FAM19A5 had 87.9% sensitivity and 52.7% specificity for identifying CAD.
Conclusions:
Serum FAM19A5 levels were negatively associated with the presence and severity of CAD and may represent a novel biomarker for diagnosing and indication the severity of CAD.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
01:30Coronary Artery Disease III: Clinical Manifestations
01:26Coronary Artery Disease II: Pathophysiology
01:26Coronary Artery Disease IV: Preventive Measures
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT